Respiratory failure & ventilation

Evaluating sedation strategies in acute respiratory distress syndrome: A meta-analysis of inhaled versus intravenous agents

J Clin AnesthPublished Systematic review and meta-analysis of randomised and observational studies

Pooled result · ICU LOSResult — go to the resultMD −2.07 days 95 % CI −3.72 to −0.41

Authors' conclusion

Inhaled sedation with volatile anesthetics may offer advantages over intravenous sedation in reducing ICU stay and mechanical ventilation duration in ARDS patients. However, the associated alterations in gas exchange parameters warrant cautious interpretation.

Study context

Population
Patients with acute respiratory distress syndrome (ARDS)
Participants
1,349 patients · 7 studies
Comparison
Inhaled vs intravenous sedation
Outcome
ICU LOS
Methodological detailsrandom-effects meta-analysis, PRISMA, Risk of bias assessed with ROB-2 and Newcastle-Ottawa tools
  • Random-effects meta-analysis
  • PRISMA
  • Risk of bias assessed with ROB-2 and Newcastle-Ottawa tools

Pooled result

As reported in the abstract

MD

−2.07 days

95 % CI −3.72 to −0.41

P = 0.01

Inhaled vs Intravenous
MD −2.07 days (95 % CI −3.72 to −0.41); P = 0.01

Further pooled results

OutcomeMD (days) (95 % CI)P value
Duration of mechanical ventilation−2.62 (−4.48 to −0.76)P = 0.006
OutcomeMD (95 % CI)P value
Ventilator-free daysSignificantly fewer VFDs with inhaled sedation−1.82 (−3.41 to −0.24)P = 0.02

Mortality

No mortality difference
P = 0.18

PEEP on day 1

Improved with inhaled agents
P < 0.00001

Safety

Gas exchange: PaCO2 and arterial pH

Increased PaCO2 with inhaled agents
P < 0.00001
Reduced arterial pH with inhaled agents
P = 0.001

Original publication

Evaluating sedation strategies in acute respiratory distress syndrome: A meta-analysis of inhaled versus intravenous agents. J Clin Anesth. Published 10 December 2025. doi:10.1016/j.jclinane.2025.112100

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.